Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | ATM | Q13315 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23221689 | 0.99 | PSMB5 (0.60) | L3MBTL1PSMB5MEN1KMT2AALDH1A1 | |
| SCHEMBL21583734 | 0.99 | PSMB5 (0.60) | L3MBTL1PSMB5MEN1KMT2AALDH1A1 | |
| SCHEMBL9237118 | 0.99 | PSMB5 (0.60) | L3MBTL1PSMB5MEN1KMT2AALDH1A1 | |
| SCHEMBL23221677 | 0.93 | LMNA (0.66) | L3MBTL1PSMB5MEN1KMT2AALDH1A1 | |
| SCHEMBL23221679 | 0.93 | LMNA (0.66) | L3MBTL1PSMB5MEN1KMT2AALDH1A1 | |
| SCHEMBL8682005 | 0.90 | L3MBTL1 (0.58) | L3MBTL1PSMB5MEN1KMT2AALDH1A1 | |
| SCHEMBL13525012 | 0.88 | ATM (0.60) | L3MBTL1ALDH1A1ATMLMNATDP1 | |
| SCHEMBL13033926 | 0.87 | LMNA (0.56) | L3MBTL1ALDH1A1ATMLMNATDP1 | |
| SCHEMBL7778087 | 0.86 | LMNA (0.71) | L3MBTL1PSMB5MEN1KMT2AALDH1A1 | |
| SCHEMBL9716670 | 0.86 | LMNA (0.71) | L3MBTL1PSMB5MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197437-A1 | COMPOSITIONS FOR ENHANCED EPITHELIAL PERMEATION OF Y2 RECEPTOR-BINDING PEPTIDES | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070161563-A1 | A DEVICE FOR ENHANCED EPITHELIAL PERMEATION OF Y2 RECEPTOR-BINDING PEPTIDES | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-07-12 | — | — | US | disclosed |
| US-7229966-B2 | Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20070129299-A1 | COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PYY PEPTIDE | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-06-07 | — | — | US | disclosed |
| US-7186691-B2 | Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7157426-B2 | such as peptide YY, Neuropeptide Y, or Pancreatic polypeptide with solubilizing agent (cyclodextran), chelating agent (ethylenediamine tetraacetic acid), and polyol such as sucrose | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1715885-A2 | COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY | Nastech Pharmaceutical Company Inc. (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20060134130-A1 | Oral drug delivery compositions and methods | EMISPHERE TECHNOLOGIES, INC. (US) | 2006-06-22 | — | — | US | disclosed |
| US-7005141-B2 | Oral drug delivery compositions and methods | EMISPHERE TECHNOLOGIES INC. (US) | 2006-02-28 | — | — | US | disclosed |
| EP-1581245-A2 | COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY | Nastech Pharmaceutical Company Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| US-6461643-B2 | CONSISTS OF AT LEAST ONE BIOLOGICALLY- ACTIVE AGENT; (B) AT LEAST ONE CARRIER COMPRISING AN ACYLATED ALDEHYDE OF AN AMINO ACID, AN ACYLATED KETONE OF AN AMINO ACID, AN ACYLATED ALDEHYDE OF A PEPTIDE, AN ACYLATED KETONE OF A PEPTIDE | EMISPHERE TECHNOLOGIES, INC. | 2002-10-08 | — | — | US | disclosed |
| US-20020052422-A1 | Oral drug delivery compositions and methods | EMISPHERE TECHNOLOGIES, INC. | 2002-05-02 | — | — | US | disclosed |
| EP-0696208-B1 | ORAL DRUG DELIVERY COMPOSITIONS | EMISPHERE TECH INC (US) | 2001-08-22 | — | — | EP | disclosed |
| EP-1077070-A2 | Oral drug delivery compositions | Emisphere Technologies, Inc. (US) | 2001-02-21 | — | — | EP | disclosed |
| EP-1025840-A2 | Oral drug compositions and methods | Emisphere Technologies, Inc. (US) | 2000-08-09 | — | — | EP | disclosed |
| US-5792451-A | AMINO ACID DERIVATIVES AS CARRIERS FOR SENSITIVE AGENTS SUCH AS BIOACTIVE PEPTIDES | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-08-11 | — | — | US | disclosed |
| US-5766633-A | MODIFIED AMINO ACID CARRIER, BIOACTIVE PEPTIDES | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-06-16 | — | — | US | disclosed |
| EP-0696208-A4 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | EMISPHERE TECH INC (US) | 1997-01-29 | — | — | EP | disclosed |
| EP-0696208-A1 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | Emisphere Technologies, Inc. (US) | 1996-02-14 | — | — | EP | disclosed |
| WO-1994023767-A1 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | EMISPHERE TECHNOLOGIES, INC. (US) | 1994-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060134130-A1 | Oral drug delivery compositions and methods | ADM2, PTMS, DNPEP | L3MBTL1 3981/4885PSMB5 1473/4885MEN1 1466/4885 |
| US-20020052422-A1 | Oral drug delivery compositions and methods | ADM2, PTMS, DNPEP | L3MBTL1 3981/4885PSMB5 1473/4885MEN1 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.